STRATA Skin Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on March 24, 2021
March 10 2021 - 8:00AM
STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the
“Company”), a medical technology company dedicated to developing,
commercializing and marketing innovative products for the treatment
of dermatologic conditions, today announced that it plans to
release its fourth quarter and full year financial results after
the market closes on Wednesday, March 24, 2021. Management will
hold a conference call to review the financial results and provide
a corporate update starting at 4:30 p.m. Eastern Time / 1:30 p.m.
Pacific Time on the same day. The conference call will be
concurrently webcast.
The link to the webcast will be available on the
STRATA Skin Sciences website
at: www.strataskinsciences.com under the investor
relations section and will be archived for future reference. To
listen to the conference call, please dial 1-877-451-6152
(US/Canada), 1-201-389-0879 (International), or 1 809 406 247
(Israel) and use the conference ID number 13717061.
About STRATA Skin Sciences,
Inc.STRATA Skin Sciences is a medical technology
company in Dermatology and Plastic Surgery dedicated to developing,
commercializing and marketing innovative products for the treatment
of dermatologic conditions. Its products include the
XTRAC® excimer laser and VTRAC® lamp systems utilized in
the treatment of psoriasis, vitiligo and various other skin
conditions.
The Company’s proprietary XTRAC® excimer
laser delivers a highly targeted therapeutic beam of UVB light to
treat psoriasis, vitiligo, eczema, atopic dermatitis and
leukoderma, diseases which impact over 31 million patients
in the United States alone. The technology is covered by
multiple patents, including exclusive rights for patents for the
delivery of treatment to vitiligo patients.
STRATA’s unique business model leverages
targeted Direct to Consumer (DTC) advertising to generate awareness
and utilizes its in-house call center and insurance advocacy teams
to increase volume for the Company’s partner dermatology
clinics.
The XTRAC business has used this proven DTC
model to grow its domestic dermatology partner network to over 832
clinics, with a worldwide installed base of over 2,300 devices. The
Company is able to offer 90% of DTC patients an introduction to
physicians prescribing a reimbursable solution, using XTRAC, within
a 10-mile radius of their house. The Company is a leader in
dermatology in-clinic business generation for its partners.
The Company has now introduced its Home by
XTRAC™ business, leveraging in-house resources; including DTC
advertising, in-house call center and its insurance reimbursement
team to provide an at-home, insurance-reimbursed treatment option
for patients with certain skin diseases that do not qualify for
in-office treatments.
Investor Relations
Contact:Leigh Salvo(415) 937-5404ir@strataskin.com
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Sep 2023 to Sep 2024